價(jià)格 | ¥198 | ¥289 | ¥529 |
包裝 | 1mg | 2mg | 5mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-12 |
中文名稱:4-[3-(甲磺?;?苯基]-1-丙基哌啶 | 英文名稱:Pridopidine |
CAS:346688-38-8 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.89% | 產(chǎn)品類別: 抑制劑 |
貨號(hào): T7352 |
名稱 | Pridopidine |
描述 | Pridopidine (FR310826), a dopamine (DA) stabilizer, acts as a low affinity dopamine D2 receptor (D2R) antagonist, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model. |
動(dòng)物實(shí)驗(yàn) | Sprague Dawley rats (n = 6) were treated daily by oral gavage with pridopidine (60 mg/kg) over 10 days. Six control Sprague Dawley rats were vehicle-treated. On the 10th day, 90 min following the last drug administration, brains were removed and RNA was isolated from the striatum of each rat and was analyzed using Affymetrix Rat 230_2 arrays. The gene expression data from 12 striatum samples was RMA normalized with affy package v1.42.3 in R v3.1.2. Probesets were annotated . The limma package v3.18.13 in R v3.1.3 was used to test if relevant calcium-related genes were differentially expressed between the two groups of biological replicates and multiple hypothesis testing was corrected for using the Bonferroni correction. Limma employs an empirical Bayes method to moderate standard error . When a gene had multiple probesets, the probeset with the highest absolute value of fold change was reported[1]. |
體內(nèi)活性 | Pridopidine的作用通過S1R介導(dǎo),導(dǎo)致YAC128 MSNs中ER Ca2+釋放、ER Ca2+水平和spine SOC入口的正?;?。這是pridopidine作用機(jī)制的一個(gè)新發(fā)現(xiàn),凸顯S1R作為HD治療的潛在靶點(diǎn)。長期使用pridopidine治療可能通過上調(diào)調(diào)節(jié)鈣的紋狀體蛋白,包括calbindin和homer1a,進(jìn)一步為HD中pridopidine的長期有益效果貢獻(xiàn)。 |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 45 mg/mL (159.91 mM) |
關(guān)鍵字 | Dopamine Receptor | inhibit | FR-310826 | Inhibitor | ACR-16 | ASP-2314 | FR 310826 | Pridopidine | ACR 16 | ASP 2314 |
相關(guān)產(chǎn)品 | Fluphenazine dihydrochloride | Octodrine | Oxolinic acid | Citicoline | Mirtazapine | Phenothiazine | Olanzapine | Mianserin hydrochloride | L-DOPA | CLOZAPINE N-OXIDE | Doxepin hydrochloride | Octopamine hydrochloride |
相關(guān)庫 | 神經(jīng)保護(hù)化合物庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | GPCR靶點(diǎn)分子庫 | 膜蛋白靶向化合物庫 | 藥物功能重定位化合物庫 | 抗癌臨床化合物庫 | 抗癌藥物庫 |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP6年
|
湖北惠擇普醫(yī)藥科技有限公司
|
2025-02-06 | |
詢價(jià) |
VIP4年
|
陜西締都醫(yī)藥化工有限公司
|
2025-01-13 | |
詢價(jià) |
VIP5年
|
上海智開醫(yī)藥科技有限公司
|
2025-02-07 |